Targeted fluorination of a nonsteroidal anti-inflammatory drug to prolong metabolic half-life
Shaughnessy, MJ; Harsanyi, A; Li, J; Bright, T; Murphy, CD; Sandford, G
In drug design, one way of improving metabolic stability is to introduce fluorine at a metabolically labile site. In the early stages of drug design, identification of such sites is challenging, and a rapid method of assessing the effect of fluorination on a putative drug’s metabolic stability would be of clear benefit. One approach to this is to employ micro-organisms that are established as models of drug metabolism in parallel with the synthesis of fluorinated drug analogues. In this study, we have used the filamentous fungus Cunninghamella elegans to identify the metabolically labile site of the nonsteroidal anti-inflammatory drug flurbiprofen, to aid in the design of fluorinated derivatives that were subsequently synthesised. The effect of the additional fluorine substitution on cytochrome P450-catalysed oxidation was then determined via incubation with the fungus, and demonstrated that fluorine substitution at the 4′-position rendered the drug inactive to oxidative transformation, whereas substitution of fluorine at either 2′ or 3′ resulted in slower oxidation compared to the original drug. This approach to modulating the metabolic stability of a drug-like compound is widely applicable and can be used to address metabolic issues of otherwise good lead compounds in drug development.
Shaughnessy, M., Harsanyi, A., Li, J., Bright, T., Murphy, C., & Sandford, G. (2014). Targeted fluorination of a nonsteroidal anti-inflammatory drug to prolong metabolic half-life. ChemMedChem, 9(4), 733-736. https://doi.org/10.1002/cmdc.201300490
|Journal Article Type||Article|
|Publication Date||Apr 1, 2014|
|Deposit Date||May 16, 2014|
|Publicly Available Date||May 21, 2014|
|Peer Reviewed||Peer Reviewed|
|Keywords||Cross-coupling reactions, Cytochrome P450s, Drug design, Fluorine, Drug metabolism.|
Accepted Journal Article
This is the peer reviewed version of the following article: Shaughnessy, M.J. and Harsanyi, A. and Li, J. and Bright, T. and Murphy, C.D. and Sandford, G. (2014) 'Targeted fluorination of a nonsteroidal anti-inflammatory drug to prolong metabolic half-life.', ChemMedChem, 9 (4). pp. 733-736 which has been published in final form at http://dx.doi.org/10.1002/cmdc.201300490. This article may be used for non-commercial purposes in accordance With Wiley-VCH Terms and Conditions for self-archiving.
You might also like
HFO-1234yf as a CF3-building block: Synthesis and Chemistry of CF3-ynones
Kinetics of electrophilic fluorination of steroids and epimerisation of fluorosteroids
Fluorocyanoesters as Additives for Lithium-Ion Battery Electrolytes